Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset Of Low Risk HER2+ Pa
 

Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

More...